Capital Advisors Ltd’s Aclaris Therapeutics ACRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2K Hold
454
– – ﹤0.01% 1205
2026
Q2
$2K Hold
454
– – ﹤0.01% 1088
2026
Q1
$2K Hold
454
– – ﹤0.01% 1067
2025
Q4
$1K Hold
454
– – ﹤0.01% 1128
2025
Q3
$1K Hold
454
– – ﹤0.01% 1123
2025
Q2
$1K Hold
454
– – ﹤0.01% 1123
2025
Q1
$1K Hold
454
– – ﹤0.01% 1112
2024
Q4
$1K Hold
454
– – ﹤0.01% 1133
2024
Q3
$1K Hold
454
– – ﹤0.01% 1127
2024
Q2
$0 Buy
+454
New +$533 ﹤0.01% 1344

Other funds holding ACRS

Capital Advisors Ltd's ACRS Position: Q3 2026 in Review

Capital Advisors Ltd held its Aclaris Therapeutics (ACRS) position steady in Q3 2026 at 454 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1205.

Capital Advisors Ltd first reported a position in ACRS in Q2 2024 and has held it in 10 quarters since. 167 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • Capital Advisors Ltd held 454 shares of Aclaris Therapeutics worth $2K as of Q3 2026.
  • Capital Advisors Ltd left its Aclaris Therapeutics share count unchanged in Q3 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q3 2026, its #1205 holding.
  • Capital Advisors Ltd first reported a position in Aclaris Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • 167 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on Capital Advisors Ltd's 13F filing for Q3 2026, filed 27 Oct 2026.